HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adrian Koh Selected Research

brolucizumab

1/2022Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
1/2022Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
1/2022Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
1/2021HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
1/2020Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
1/2020HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Adrian Koh Research Topics

Disease

9Macular Degeneration (Age-Related Maculopathy)
01/2022 - 05/2017
8Polypoidal Choroidal Vasculopathy
01/2022 - 09/2012
4Diabetic Retinopathy (Retinopathy, Diabetic)
01/2022 - 01/2021
3Polyps
01/2022 - 09/2012
3COVID-19
03/2021 - 06/2020
2Retinal Vein Occlusion
01/2022 - 01/2022
2Vascular Diseases (Vascular Disease)
01/2022 - 01/2022
2Retinal Diseases
03/2021 - 06/2020
2Macular Edema
11/2019 - 07/2015
2Vision Disorders (Hemeralopia)
05/2017 - 07/2015
2Atrophy
10/2016 - 12/2009
2Hemorrhage
07/2015 - 11/2004
1Inflammation (Inflammations)
01/2022
1Choroidal Neovascularization
01/2022
1Infections
03/2021
1Cicatrix (Scar)
01/2021
1Cataract (Cataracts)
09/2020
1Glaucoma
09/2020
1Blindness (Hysterical Blindness)
05/2017
1Ischemia
07/2015
1Dengue (Dengue Fever)
11/2004
1Retinal Degeneration
07/2004
1Myopia
03/2002

Drug/Important Bio-Agent (IBA)

7afliberceptIBA
01/2022 - 05/2017
6brolucizumabIBA
01/2022 - 01/2020
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2021 - 05/2017
6Ranibizumab (Lucentis)FDA Link
08/2020 - 09/2012
5Retinaldehyde (Retinal)IBA
01/2022 - 11/2004
3Verteporfin (Visudyne)FDA Link
01/2020 - 09/2012
21-phenyl-3,3-dimethyltriazene (PDT)IBA
01/2022 - 09/2012
2SteroidsIBA
09/2020 - 11/2019
2Mydriatics (Cycloplegics)IBA
07/2004 - 03/2002
1salicylhydroxamic acid (SHAM)IBA
01/2022
1Biomarkers (Surrogate Marker)IBA
01/2022
1Immunoglobulin FragmentsIBA
01/2020
1Dexamethasone (Maxidex)FDA LinkGeneric
10/2016
1Indocyanine Green (Cardio-Green)FDA LinkGeneric
09/2012
1Retinal Pigments (Pigments, Visual)IBA
12/2009
1AntibodiesIBA
11/2004
1Immunoglobulin M (IgM)IBA
11/2004
1EnzymesIBA
11/2004
1Ophthalmic Solutions (Eye Drops)IBA
03/2002
1AtropineFDA LinkGeneric
03/2002

Therapy/Procedure

5Therapeutics
01/2020 - 05/2017
4Injections
01/2022 - 10/2016
3Photochemotherapy (Photodynamic Therapy)
01/2020 - 09/2012
2Intravitreal Injections
03/2021 - 06/2020
2Lasers (Laser)
11/2019 - 07/2015
1Personal Protective Equipment
03/2021
1Treatment Delay
01/2021
1Light Coagulation
11/2019
1Contact Lenses
03/2002
1Lenses
03/2002
1Hydrophilic Contact Lenses (Hydrophilic Contact Lens)
03/2002